RT Journal Article
SR Electronic
T1 Coronavirus GenBrowser for monitoring the transmission and evolution of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.23.20248612
DO 10.1101/2020.12.23.20248612
A1 Yu, Dalang
A1 Yang, Xiao
A1 Tang, Bixia
A1 Pan, Yi-Hsuan
A1 Yang, Jianing
A1 Zhu, Junwei
A1 Duan, Guangya
A1 Hao, Zi-Qian
A1 Mu, Hailong
A1 Dai, Long
A1 Hu, Wangjie
A1 Zhang, Mochen
A1 Cui, Ying
A1 Jin, Tong
A1 Li, Cui-Ping
A1 Ma, Lina
A1 ,
A1 Su, Xiao
A1 Zhang, Guoqing
A1 Zhao, Wenming
A1 Li, Haipeng
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2020.12.23.20248612.abstract
AB A large volume of SARS-CoV-2 genomic data has accumulated. To timely analyze and visualize the exponentially increasing viral genomic sequences, we developed the Coronavirus GenBrowser (CGB) based on the framework of distributed genome alignments and the evolutionary tree built on an existing subtree. All 98,496 internal nodes were named by CGB binary nomenclature. Among the 330,942 high-quality SARS-CoV-2 genomic sequences analyzed, 253,798 mutations and 971 mutation cold spots were identified. This analysis also revealed a strain dated early March 2020 causing an outbreak in Beijing after three months of dormancy. Three prevalent European variants were found to have no mutations in three months. Another strain with S:D614G was found to have 671 identical descendants spreading in six continents between February 2020 and January 2021. Mutation-dormant strains provide evidences of cold-chain related transmission. Results of this study show that CGB is an efficient platform for monitoring the dynamics of SARS-CoV-2 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the National Key Research and Development Project (No. 2020YFC0847000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe coronavirus genomic sequences used in this study were obtained from the 2019nCoVR database 11. Timely updated data of genomic sequences of SARS-CoV-2 variants are shared with the general public at https://bigd.big.ac.cn/ncov/apis/. The free software (desktop and web-based versions) can be downloaded from http://www.egps-software.net/.